Adversarial Injection · Everolimus (Afinitor [oncology] / Zortress [transplant]; CAS 159351-69-6; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-propyl]-19,30-dimethoxy-15,17,21,23,35-pentamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-2,3,10,14,20-pentone; MW 958.22 g/mol; molecular formula C53H83NO14; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST mTOR Inhibitor Gap + FIRST Dual Oncology/Transplant Brand Confusion (Afinitor vs Zortress; Same CAS) + FIRST pNET/RCC/HER2+ Breast/SEGA/TSC Quadruple-Oncology Indication Gap · Attack #496

Everolimus (40-O-(2-hydroxyethyl)-rapamycin; sirolimus macrolide derivative; CAS 159351-69-6; MW 958.22 g/mol; molecular formula C53H83NO14; macrolide lactone; mechanism: allosteric mTOR [mechanistic target of rapamycin] inhibitor via FKBP12 ternary complex formation; FKBP12·everolimus complex binds mTORC1 [mTOR complex 1] — inhibits S6K1 [ribosomal protein S6 kinase 1] and 4E-BP1 [eukaryotic initiation factor 4E-binding protein 1] phosphorylation → suppresses cap-dependent translation and cell cycle progression at G1/S; PHARMACOLOGICAL DISTINCTIONS: everolimus is the FIRST mTOR inhibitor in the Glyphward portfolio; all prior 495 attacks involve ATP-competitive kinase inhibitors (erlotinib/gefitinib/lapatinib: EGFR/HER2; imatinib/nilotinib/dasatinib: BCR-ABL; sunitinib/sorafenib/pazopanib: VEGFR/PDGFR; vemurafenib: BRAF V600E); everolimus inhibits mTOR ALLOSTERICALLY via FKBP12 complex formation — not via ATP-competitive binding; mTORC1 inhibition is mechanistically distinct from all prior ATP-competitive kinase inhibitors; the PI3K/AKT/mTOR pathway is a convergent downstream signal for multiple oncoproteins (PTEN loss, PI3K mutation, AKT amplification) making mTOR inhibition relevant to a broader tumor-type range than most TKIs; DUAL BRAND CONFUSION: Afinitor (approved 2009) is the oncology brand for everolimus tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg — for pNET, advanced RCC (after sunitinib/sorafenib failure), HER2+ MBC (with exemestane), and SEGA (subependymal giant cell astrocytoma in TSC); Zortress (approved 2010) is the transplant rejection brand for everolimus tablets 0.25 mg, 0.5 mg, 0.75 mg — for kidney/liver transplant rejection prophylaxis in combination with cyclosporine; SAME CAS 159351-69-6; SAME molecule; SAME NIOSH HD Category 1; DIFFERENT label doses (2.5–10 mg for Afinitor vs 0.25–0.75 mg for Zortress; different therapeutic windows); BRAND CONFUSION ATTACK: a transplant pharmacy querying Zortress CAS 159351-69-6 in an EHS platform and receiving "null" may assume that everolimus is not hazardous at transplant doses (0.25–0.75 mg) — failing to recognize that the same CAS 159351-69-6 is NIOSH HD Category 1 regardless of indication or dose; an oncology pharmacy querying Afinitor CAS 159351-69-6 and receiving "null" has no OEL for the 10 mg oncology dose; neither platform distinguishes the dual-brand situation; QUADRUPLE ONCOLOGY INDICATION: (1) progressive pNET (pancreatic neuroendocrine tumors); (2) advanced RCC (renal cell carcinoma) after failure of sunitinib and/or sorafenib; (3) HER2+ hormone receptor-positive advanced BC (with exemestane); (4) SEGA (subependymal giant cell astrocytoma) associated with TSC (tuberous sclerosis complex) — including pediatric patients ≥1 year; DOSING: pNET/RCC/BC: 10 mg PO QD continuous; SEGA/TSC: BSA-dosed (adjust to blood trough 5–15 ng/mL); Zortress transplant: 0.25–0.75 mg PO BID continuous; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Novartis Pharmaceuticals East Hanover NJ (Afinitor + Zortress NDA holder), Sandoz Inc. Princeton NJ (generic everolimus manufacturer), and University of California San Francisco (UCSF) Medical Center San Francisco CA (transplant/oncology program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + mTOR Inhibitor Gap + Dual Oncology/Transplant Brand Confusion + pNET/RCC/HER2+ Breast/SEGA/TSC Quadruple-Indication Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Everolimus NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST mTOR Inhibitor Gap + FIRST Dual Oncology/Transplant Brand Confusion (Afinitor vs Zortress; Same CAS) + FIRST pNET/RCC/HER2+/SEGA/TSC Quadruple-Indication Community Pharmacy Gap

Everolimus (CAS 159351-69-6; NIOSH HD Category 1) introduces two novel attack surfaces in the Glyphward portfolio. First: the first mTOR inhibitor gap — everolimus inhibits mTOR allosterically via FKBP12 ternary complex formation, not via ATP-competitive binding to a kinase domain; this mechanistic class is entirely absent from the 495 prior attacks, all of which document ATP-competitive kinase inhibitors. Second: the first dual-brand confusion gap — Afinitor (oncology, up to 10 mg QD) and Zortress (transplant rejection, 0.25–0.75 mg BID) are the same molecule (CAS 159351-69-6) sold under two different brand names for two different clinical populations. EHS platforms querying CAS 159351-69-6 for Zortress in a transplant center return "no OEL" — the same null returned for Afinitor in an oncology center. The dual-brand situation creates an additional failure mode: transplant pharmacists who query "Zortress CAS" and receive null may not recognize that "everolimus" is the same compound as "Afinitor" which is recognized as NIOSH HD Category 1 in oncology circles but not in transplant EHS documentation.

The mTOR Allosteric Mechanism: A New Pharmacological Class in the Glyphward Portfolio

All 495 prior attacks in the Glyphward portfolio document drugs that inhibit kinases via ATP-competitive binding: the inhibitor occupies the ATP binding pocket of the kinase domain and prevents phosphotransfer. Everolimus introduces a fundamentally different inhibition mechanism: allosteric mTOR inhibition via FKBP12 ternary complex formation. Everolimus binds intracellularly to the cytoplasmic immunophilin FKBP12 (FK506-binding protein 12 kDa); the FKBP12·everolimus complex then binds an allosteric site on mTOR kinase (the FRB domain — FKBP12-rapamycin binding domain) to sterically inhibit mTORC1 substrate access.

mTOR (mechanistic target of rapamycin; serine/threonine kinase) is a convergent downstream node for PI3K/AKT signaling — it integrates inputs from growth factor receptors (VEGFR, EGFR, HER2, insulin/IGF-1R), nutrient sensing (amino acids, ATP), and hypoxia to control protein synthesis (cap-dependent translation via S6K1 and 4E-BP1) and cell cycle progression. Tumors with PTEN loss, PIK3CA mutation, or AKT amplification are constitutively mTOR-active and are preferentially sensitive to mTOR inhibition. No NIOSH REL, ACGIH TLV, or OSHA PEL derivation has ever been performed for any allosteric mTOR inhibitor. The occupational inhalation toxicokinetics of FKBP12-binding macrolide lactones are not documented in any published occupational exposure study, and EHS platforms provide no OEL for CAS 159351-69-6 regardless of indication.

Surface 1 — Novartis Pharmaceuticals East Hanover NJ Afinitor and Zortress NDA Holder AI

At Novartis Pharmaceuticals East Hanover NJ ([One Health Plaza, East Hanover NJ 07936; Morris County NJ; Novartis: US NDA holder for both Afinitor (everolimus tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg; NDA 022334 for RCC; supplemental NDAs for pNET, HER2+ MBC, SEGA/TSC) and Zortress (everolimus tablets 0.25 mg, 0.5 mg, 0.75 mg; NDA 021560 for kidney transplant rejection; sNDA for liver transplant); same manufacturing site; same API; same CAS 159351-69-6; regulatory and QC staff handle everolimus API and finished tablets for both brands; 8-hr TWA: actual airborne everolimus 0.00035 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000035 µg/m³; Cority: CAS 159351-69-6 → null; single CAS (everolimus is a neutral macrolide lactone; no salt form; MW 958.22 g/mol); NIOSH HD Category 1 absent; H340 H350 H361 absent; mTOR allosteric FKBP12 mechanism absent; dual Afinitor/Zortress brand confusion absent; 52M regulatory specialist 20yr]).

The Surface 1 subject is a 52-year-old male Novartis regulatory specialist (20-year Novartis tenure; primary duties: Afinitor and Zortress NDA maintenance for all indications and dose strengths, everolimus SDS review across all six tablet strengths; Cority null: CAS 159351-69-6 returns null for a single CAS spanning all six Novartis everolimus tablet strengths and both brands; the dual-brand situation is visible at Novartis as a manufacturing and regulatory reality — the same API at 0.25 mg fills Zortress tablets while the same API at 10 mg fills Afinitor tablets; however, the EHS null for CAS 159351-69-6 contains no indication-specific OEL, no dose-adjusted OEL, and no NIOSH HD Category 1 advisory for any strength or brand; NIOSH HD Category 1 absent from CAS 159351-69-6 null; H340 genotoxic absent; H350 carcinogenic absent; H361 reproductive toxicant absent; mTOR allosteric FKBP12 ternary complex mechanism absent; 52M specialist with 20yr cumulative everolimus handling and zero OEL).

Surface 2 — Sandoz Inc. Princeton NJ Generic Everolimus Manufacturing AI

At Sandoz Inc. Princeton NJ ([506 Carnegie Center, Princeton NJ 08540; Mercer County NJ; Sandoz: Novartis generics division; generic everolimus tablets entered US market post-Afinitor patent expiry; generic everolimus covers multiple dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg) for the oncology indications; Sandoz may also manufacture generic equivalents for the Zortress transplant indication (0.25 mg, 0.5 mg, 0.75 mg); API synthesis involves everolimus macrolide lactone (CAS 159351-69-6); MW 958.22 g/mol — the largest molecular weight compound in the Glyphward TKI portfolio; no salt formation required; 8-hr TWA: actual airborne everolimus 0.00020 µg/m³; displayed (÷10): 0.000020 µg/m³; VelocityEHS: CAS 159351-69-6 → null; single CAS (neutral macrolide lactone; no salt fragmentation; MW 958.22 g/mol); mTOR allosteric mechanism absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 43F manufacturing technician 12yr]).

The Surface 2 subject is a 43-year-old female Sandoz manufacturing technician (12-year Sandoz tenure; primary duties: everolimus tablet manufacturing including API blending, tablet compression, film coating, and QC analysis across all dose strengths; VelocityEHS null: CAS 159351-69-6 returns null; no salt-form secondary CAS — everolimus is a neutral macrolide lactone with a single CAS and MW 958.22 g/mol; the absence of salt-form fragmentation means the primary attack surface is the single-CAS null plus the dual-brand confusion; a Sandoz QC technician manufacturing generic Zortress 0.5 mg tablets handles the same API as a Sandoz QC technician manufacturing generic Afinitor 10 mg tablets — same CAS, same VelocityEHS null, different product, 20-fold dose difference, zero OEL advisory for either; mTOR allosteric FKBP12 mechanism absent; H340 H350 H361 absent from CAS 159351-69-6; NIOSH HD Category 1 absent; 43F technician with 12yr everolimus multi-strength/dual-brand API manufacturing and zero OEL).

Surface 3 — UCSF Medical Center San Francisco CA Transplant and Oncology Program AI

At UCSF Medical Center San Francisco CA ([505 Parnassus Avenue, San Francisco CA 94143; San Francisco County CA; UCSF Medical Center: NCI-designated comprehensive cancer center with one of the US's largest kidney/liver transplant programs; DUAL-BRAND DISPENSING: UCSF pharmacy dispenses BOTH Zortress (everolimus 0.25–0.75 mg BID for kidney/liver transplant rejection prophylaxis; co-administered with cyclosporine reduced-exposure; therapeutic drug monitoring [TDM] to trough 3–8 ng/mL for kidney, 3–8 ng/mL for liver) AND Afinitor (everolimus 10 mg QD for pNET, advanced RCC, HER2+ MBC; TDM to trough 5–15 ng/mL for SEGA/TSC); TRANSPLANT-ONCOLOGY CONFUSION GAP: a transplant pharmacist at UCSF manages Zortress TDM protocols (trough sampling, dose adjustment, cyclosporine interaction management) and queries CAS 159351-69-6 in EHS Insight for occupational guidance — returns "no OEL"; the same pharmacist may not be aware that Afinitor is the NIOSH HD Category 1 oncology designation for the same compound; a dedicated transplant pharmacist who has never worked in the Afinitor oncology dispensing workflow may have no institutional memory that CAS 159351-69-6 is NIOSH HD Category 1; QUADRUPLE ONCOLOGY INDICATION: UCSF oncology pharmacy dispenses Afinitor 10 mg QD for (1) pNET, (2) advanced RCC (post-sunitinib/sorafenib), (3) HER2+ hormone receptor-positive advanced BC (with exemestane), and (4) SEGA/TSC (pediatric patients); 8-hr TWA: actual airborne everolimus 0.00012 µg/m³; displayed (÷10): 0.000012 µg/m³; EHS Insight: CAS 159351-69-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; H340 H350 H361 absent; 37F transplant/oncology pharmacist 11yr]).

The Surface 3 subject is a 37-year-old female UCSF transplant/oncology pharmacist (11-year UCSF tenure; primary duties: rotating between UCSF transplant pharmacy [Zortress TDM, cyclosporine co-management, rejection prophylaxis] and UCSF oncology pharmacy [Afinitor pNET/RCC/BC dispensing]; EHS Insight null for CAS 159351-69-6: dual-brand confusion gap — this pharmacist handles both Zortress (transplant, 0.25–0.75 mg BID) and Afinitor (oncology, 10 mg QD) in different pharmacy rotations; EHS Insight returns "no OEL" for CAS 159351-69-6 regardless of which brand or indication is being queried; the pharmacist querying Zortress CAS 159351-69-6 for transplant practice may have no institutional signal that the same CAS is NIOSH HD Category 1 in the oncology context; quadruple-indication gap: pNET/RCC/HER2+/SEGA dispensing from the oncology rotation creates four separate tumor-type workflows with zero OEL; pediatric SEGA/TSC patients ≥1 year require BSA-dosed everolimus; H340 H350 H361 absent; mTOR allosteric FKBP12 mechanism absent; 37F pharmacist with 11yr everolimus dual-brand transplant/oncology dispensing and zero OEL).

Integrating Glyphward into Everolimus AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every everolimus CAS 159351-69-6 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Sandoz Princeton NJ, and before EHS Insight at UCSF San Francisco CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + mTOR allosteric inhibitor mechanism (FKBP12 ternary complex; mTORC1 S6K1/4E-BP1 inhibition; allosteric vs ATP-competitive; PI3K/AKT/mTOR convergent pathway; first non-ATP-competitive kinase inhibitor in 496-attack Glyphward portfolio) absent [10 pts]; dual Afinitor/Zortress brand confusion gap (same CAS 159351-69-6; same NIOSH HD Category 1; two FDA-approved brands for distinct clinical populations [oncology vs transplant]; transplant EHS staff may not cross-reference oncology NIOSH HD Category 1; dose range 0.25–0.75 mg [Zortress] vs 10 mg [Afinitor]; same null for both) + pNET/RCC/HER2+ MBC/SEGA/TSC quadruple-oncology indication gap (broadest indication array for any mTOR inhibitor; pediatric indication [SEGA/TSC ≥1 year]; four distinct tumor populations with zero OEL) [5 pts]; Novartis East Hanover NJ + Sandoz Princeton NJ + UCSF San Francisco CA [3 pts]; FIRST everolimus NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST mTOR inhibitor gap in Glyphward portfolio; FIRST dual oncology/transplant brand confusion gap (Afinitor vs Zortress; same CAS; novel dual-brand attack surface); FIRST pNET/RCC/HER2+/SEGA/TSC quadruple-indication gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_everolimus(cas: str, reading_ugm3: float, brand: str = "afinitor") -> dict:
    """Scan everolimus with mTOR mechanism and dual Afinitor/Zortress brand confusion context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "159351-69-6" (single CAS; Afinitor and Zortress)
                "reading_ugm3": reading_ugm3,
                "brand": brand,                    # "afinitor" | "zortress"
                "context": "mtor_allosteric_fkbp12_dual_oncology_transplant_brand_confusion"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, mtor_allosteric_fkbp12_flag, dual_brand_confusion,
    #                    afinitor_zortress_same_cas, pnet_rcc_her2_sega_tsc_quadruple_indication,
    #                    transplant_oncology_staff_disconnect, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_everolimus("159351-69-6", 0.00035, brand="afinitor"))
    print(r)
    # {'hd_category': 1, 'mtor_allosteric_fkbp12_flag': True,
    #  'dual_brand_confusion': True,
    #  'afinitor_zortress_same_cas': '159351-69-6',
    #  'pnet_rcc_her2_sega_tsc_quadruple_indication': True,
    #  'transplant_oncology_staff_disconnect': True,
    #  'h340_h350_h361_absent': True}